SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014250
Filing Date
2023-08-09
Accepted
2023-08-09 16:06:01
Documents
86
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q adap-20230630x10q.htm   iXBRL 10-Q 1865378
2 EX-31.1 adap-20230630xex31d1.htm EX-31.1 9822
3 EX-31.2 adap-20230630xex31d2.htm EX-31.2 10565
4 EX-32.1 adap-20230630xex32d1.htm EX-32.1 6131
5 EX-32.2 adap-20230630xex32d2.htm EX-32.2 6113
  Complete submission text file 0001558370-23-014250.txt   8354980

Data Files

Seq Description Document Type Size
6 EX-101.SCH adap-20230630.xsd EX-101.SCH 58773
7 EX-101.CAL adap-20230630_cal.xml EX-101.CAL 55892
8 EX-101.DEF adap-20230630_def.xml EX-101.DEF 229538
9 EX-101.LAB adap-20230630_lab.xml EX-101.LAB 458946
10 EX-101.PRE adap-20230630_pre.xml EX-101.PRE 366006
80 EXTRACTED XBRL INSTANCE DOCUMENT adap-20230630x10q_htm.xml XML 1617619
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37368 | Film No.: 231155109
SIC: 2836 Biological Products, (No Diagnostic Substances)